Silverarc Capital Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Silverarc Capital Management’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-160,526	Closed	-$1.57M	–	82
2021 Q4	$1.57M	Buy	160,526 +123,277	+331%	+$2.32M	0.64%	46
2021 Q3	$1.27M	Sell	37,249 -8	-0%	-$255	0.72%	47
2021 Q2	$1.36K	Sell	37,257 -2,508	-6%	-$97.1K	0.61%	59
2021 Q1	$1.78M	Buy	39,765 +1,145	+3%	+$53.3K	0.97%	37
2020 Q4	$2.2M	Buy	+38,620	New	+$2.29M	1.28%	30

Other funds holding DCPH

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Silverarc Capital Management's DCPH Position: Q1 2022 in Review

Silverarc Capital Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q1 2022, closing a stake of 160,526 shares — an estimated $1.57M sold.

Silverarc Capital Management first reported a position in DCPH in Q4 2020 and held it in 5 quarters. The position peaked at $2.2M in Q4 2020. 123 funds tracked by Wall St. Rank hold DCPH as of Q1 2022.

Silverarc Capital Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Silverarc Capital Management sold 160,526 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $1.57M.
Silverarc Capital Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
Silverarc Capital Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $2.2M in Q4 2020.
123 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on Silverarc Capital Management's 13F filing for Q1 2022, filed 13 May 2022.